Biodegradable, polymeric nanoparticle delivery systems for cancer therapy

Nanomedicine

Volumn 2, Issue 5, 2007, Pages 669-680

  Pridgen, Eric M ^a,b   Langer, Robert ^a,b   Farokhzad, Omid C ^b,c  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b Massachusetts Institute of Technology Cambridge   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Biodegradable polymers; Cancer therapy; Nanoparticles; Targeted

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CERAMIDE; CETUXIMAB; DENDRIMER; DEXTRAN; DNA; DOXORUBICIN; FERUMOXSIL; IRON OXIDE; MACROGOL; MESSENGER RNA; MONOCLONAL ANTIBODY; NANOPARTICLE; PACLITAXEL; PEPTIDE DERIVATIVE; PHOSPHOLIPID; PHOTOSENSITIZING AGENT; POLYAMIDOAMINE; POLYGLACTIN; POLYLACTIC ACID; POLYMER; PROTEIN DERIVATIVE; SMALL INTERFERING RNA; SUPERPARAMAGNETIC IRON OXIDE; TETANUS TOXOID; TRASTUZUMAB; UNINDEXED DRUG; VIRUS VECTOR; VIVAGEL;

BIOCOMPATIBILITY; BIODEGRADABILITY; CANCER GENE THERAPY; CANCER RESISTANCE; CLINICAL TRIAL; COLON CANCER; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RELEASE; DRUG RESEARCH; DRUG SOLUBILITY; DRUG STABILITY; DRUG TARGETING; ENCAPSULATION; HUMAN; HYPERTHERMIC THERAPY; KIDNEY CANCER; LIVER CANCER; LIVER DISEASE; LUNG CANCER; MOLECULAR IMAGING; NANOTECHNOLOGY; NEOPLASM; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; OPSONIZATION; OVARY CANCER; PARTICLE SIZE; PH; PHOTOTHERAPY; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SPLEEN DISEASE; TEMPERATURE; VIRAL GENE DELIVERY SYSTEM;

ABSORBABLE IMPLANTS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; NANOMEDICINE; NANOPARTICLES; NEOPLASMS;

EID: 37249093948     PISSN: 17435889     EISSN: None     Source Type: Journal    
DOI: 10.2217/17435889.2.5.669     Document Type: Review

References (93)

1. Harries M, Ellis P, Harper P: Nanoparticle albumin-bound paclitaxel for metastatic breast cancer. J. Clin. Oncol. 23(31), 7768-7771 (2005).
2. Gordon EM, Hall FL: Nanotechnology blooms, at last (Review). Oncol. Rep. 13(6), 1003-7 (2005).
3. Gordon EM, Lopez FF, Cornelio GH et al.: Pathotropic nanoparticles for cancer gene therapy Rexin-G IV: three-year clinical experience. Int. J. Oncol. 29(5), 1053-1064 (2006).
4. Jain RA: The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials 21(23), 2475-2490 (2000).
5. Shive MS, Anderson JM: Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv. Drug Deliv. Rev. 28(1), 5-24 (1997).
6. Langer R: Drug delivery. Drugs on target. Science 293(5527), 58-59 (2001).
7. Cheng J, Teply BA, Sherift I et a.: Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials 28(5), 869-876 (2007).
8. Desai MP, Labhasetwar V, Walter E, Levy RJ, Amidon GL: The mechanism of uptake of biodegradable microparticles in Caco-2 cells is size dependent. Pharm. Res. 14 (11), 1568-1573 (1997).
9. Farokhzad OC, Jon S, Khademhosseini A et al.: Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Res. 64(21), 7668-7672 (2004).
10. Desai MP, Labhasetwar V, Amidon GL, Levy RJ: Gastrointestinal uptake of biodegradable microparticles: effect of particle size. Pharm. Res. 13(12), 1838-1845 (1996).
11. Moghimi SM, Hunter AC: Recognition by macrophages and liver cells of opsonized phospholipid vesicles and phospholipid headgroups. Pharm. Res. 18(1), 1-8 (2001).
12. Moghimi SM, Szebeni J: Stealth liposomes and long circulating nanoparticies: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog. Lipid Res. 42(6), 463-478 (2003).
13. Gref R, Minamitake Y, Peracchia MT et al.: Biodegradable long-circulating polymeric nanospheres. Science 263(5153), 1600-1603 (1994).
14. Labhasetwar V: Nanoparticles for drug delivery. Pharm. News 4 28-31 (1997).
15. Yoo HS, Oh JE, Lee KH, Park TG: Biodegradable nanoparticles containing doxorubicin-PLGA conjugate for sustained release. Pharm. Res. 16(7), 1114-1118 (1999).
16. Yoo HS, Park TG: Folate receptor targeted biodegradable polymeric doxorubicin micelles. J. Control Release 96(2), 273-283 (2004).
17. Yoo HS, Lee EA, Park TG: Doxorubicin-conjugated biodegradable polymeric micelles having acid-cleavable linkages. J. Control Release 82 (1), 17-27 (2002).
18. Tomlinson R, Heller J, Brocchini S, Duncan R: Polyacetal-doxorubicin conjugates designed for pH-dependent degradation. Bioconjug. Chem. 14(6), 1096-1106 (2003).
19. Tomlinson R, Klee M, Garrett S et al.: Pendant chain functionalized polyacetals that display pH-dependent degradation: a platform for the development of novel polymer therapeutics. Macromolecules 35 473-480 (2002).
20. Langer R: Drug delivery and targeting. Natuir 392(6679 Suppl), 5-10 (1998).
21. LaVan DA, McGuire T, Langer R: Small-scale systems for in vivo drug delivery. Nat. Biotechnol. 21(10), 1184-1191 (2003).
22. Vila A, Sanchez A, Tobio, M, Calvo, P, Alonso MJ: Design of biodegradable particles for protein delivery. J. Control Release 78(1-3), 15-24 (2002).
23. Prego C, Torres D, Alonso MJ: Chitosan nanocapsules as carriers for oral peptide delivery: effect of chitosan molecular weight and type of salt on the in vitro behaviour and in vivo effectiveness. J. Nanosci. Nanotechnol. 6(9-10), 2921-2928 (2006).
24. Solbrig CM, Saucier-Sawyer JK, Cody V, Saltzman WM, Hanlon DJ: Polymer nanoparticles for immunotherapy from encapsulated tumor-associated antigens and whole tumor cells. Mol. Pbarm. 4(1), 47-57 (2007).
25. Raghuvanshi RJ, Mistra A, Talwar GP, Levy RJ, Labhasetwar V: Enhanced immune response with a combination of alum and biodegradable nanoparticles containing tetanus toxoid. J. Microencapsul. 18 723-732 (2001).
26. Gao D, Agayan RR, Xu H, Philbert MA, Kopelman R: Nanoparticles for two-photon photodynamic therapy in living cells. Nano Lett. 6(11), 2383-2836 (2006).
27. McCarthy JR, Perez JM, Bruckner C, Weissleder R: Polymeric nanoparticle preparation that eradicates tumors. Nano. Lett. 5(12), 2552-2556 (2005).
28. Langer R: Polymeric delivery systems for controlled drug release. Chem. Eng. Commun. 6 15-48 (1980).
29. Stepmann J, Gopferich A: Mathematical modeling of bioerudible, polymeric drug delivery systems. Adv. Drug Deliv. Rev. 48(2-3), 229-247 (2001).
30. Heffernan MJ, Murthy N: Polyketal nanoparticles: a new pH-sensitive biodegradable drug delivery vehicle. Bioconjug. Chem. 16(6), 1340-1342 (2005).
31. Seow WY, Xue JM, Yang YY: Targeted and intracellular delivery of paclitaxel using multi-functional polymeric micelles. Biomaterials 28(9), 1730-1840 (2007).
32. Shenoy D, Little S, Langer R, Amiji M: Poly(ethylene oxide)-modified poly(beta-amino ester) nanoparticles as a pH-sensitive system for tumor-targeted delivery of hydrophobic drugs. 1. In vitro evaluations. Mol. Pharm. 2(5), 357-366 (2005).
33. Meyer DE, Shin BC, Kong GA, Dewhirst MW, Chilkoti A, Drug targeting using thermally responsive polymers and local hyperthermia. J. Control, Release 74(1-3), 213-224 (2001).
34. Han HD, Choi MS, Hwang T et al.: Hyperthermia-induced antitumor activity of thermosensitive polymer modified temperature-sensitive liposomes. J. Pharm. Sci. 95(9), 1909-1917 (2006).
35. Choi SH, Lee SH, Park TG: Temperature-sensitive pluronic/ poly(ethylenimine) nanocapsules for thermally triggered disruption of intracellular endosomal compartment. Biomacromolecules 7 (6), 1864-1870 (2006).
36. Sengupta S, Eavarone D, Capila I et al.: Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature 436(7050), 568-572 (2005).
37. van Vlerken LE, Duan Z, Seiden MV, Amiji MM: Modulation of intracellular ceramide using polymeric nanoparticles to overcome multidrug resistance in cancer. Cancer Res. 67(10), 4843-4850 (2007).
38. Kim K, Lee M, Park H et al.: Cellpermeable and biocompatible polymeric nanoparticles for apoptosis imaging. J. Am. Chem. Soc. 128(11), 3490-3491 (2006).
39. Montet X, Weissleder R, Josephson L: Imaging pancreatic cancer with a peptide-nanoparticle conjugate targeted to normal pancreas. Bioconjug. Chem. 17(4), 905-911 (2006).
40. Nasongkla N, Bey E, Ren J et al.: Multifunctional polymeric micelles as cancer-targeted, MRI-ultrasensitive drug delivery systems. Nano. Lett. 6(11), 2427-2430 (2006).
41. Elbashir SM, Harborth J, Lendeckel W et al.: Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411(6836), 494-498 (2001).
42. El-Aneed A: An overview of current delivery systems in cancer gene therapy. J. Control. Release 94(1), 1-14 (2004).
43. Kay MA, Glorioso JC, Naldini L: Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat. Med. 7(1), 33-40 (2001).
44. Merdan T, Kopecek J, Kissel T: Prospects for cationic polymers in gene and oligonucleotide therapy against cancer. Adv. Drug Deliv. Rev. 54(5), 715-758 (2002).
45. Anderson DG, Akinc A, Hossain N, Langer R: Structure/property studies of polymeric gene delivery using a library of poly(beta-amino esters). Mol. Ther. 11(3), 426-434 (2005).
46. Anderson DG, Peng W, Akinc A et al.: A polymer library approach to suicide gene therapy for cancer. Proc. Natl Acad. Sci. USA 101(45), 16028-16033 (2004).
47. Green JJ, Shi J, Chiu E et al.: Biodegradable polymeric vectors for gene delivery to human endothelial cells. Bioconfug. Chem. 17(5), 1162-1169 (2006).
48. Hu-Lieskovan S, Heidel JD, Bartlett DW, Davis ME, Triche TJ: Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res. 65(19), 8984-8992 (2005).
49. Schiffelers RM, Ansari A, Xu J et al.: Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res. 32(19), e149 (2004).
50. Urban-Klein B, Werth S, Abuharbeid S, Czubayko F, Aigner A: RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther. 12(5), 461-466 (2005).
51. Wang Y, Gac, S, Ye WH, Yoon HS, Yang YY: Co-delivery of drugs and DNA from cationic core-shell nanoparticles self-assembled from a biodegradable copolymer. Nat. Mater. 5(10), 791-796 (2006).
52. Patri AK, Majoros IJ, Baker JR: Dendritic polymer macromolecular carriers for drug delivery. Curr. Opin. Chem. Biol. 6(4), 466-471 (2002).
53. Lee CC, MacKay JA, Frechet JM, Szoka FC: Designing dendrimers for biological applications. Nat. Biotechnol. 23(12). 1517-1526 (2005).
54. Duncan R, Izzo L: Dendrimer biocompatibility and toxicity Adv. Drug Deliv. Rev. 57(15), 2215-2237 (2005).
55. Roberts JC, Bhalgat MK, Zera RT: Preliminary biological evaluation of polyamidoamine (PAMAM) Starburst dendrimers. J. Biomed. Mater. Res. 30(1), 53-65 (1996).
56. Lee CC, Gillies ER, Fox ME et al.: A single dose of doxorubicin-functionalized bow-tie dendrimer cures mice bearing C-26 colon carcinomas. Proc. Natl Acad. Sci. USA 103(45), 16649-16654 (2006).
57. Luo D, Haverstick K, Belcheva N, Han E, Saltzman WM: Poly(ethylene glycol)-conjugated PAMAM dendrimer for biocompatible, high-efficiency DNA delivery. Macromolecules 35 3456-3462 (2002).
58. Wood KC, Little SR, Langer R, Hammond PT. A Family of hierarchically self-assembling linear-dendritic hybrid polymers for highly efficient targeted gone delivery. Angew. Chem. Int. Ed. 44, 6704-6708 (2005).
59. Myc A, Majoros IJ, Thomas TP, Baker JR Jr: Dendrimer-based targeted delivery of an apoptotic sensor in cancer cells. Biomacromolecules 8(1), 13-18 (2007).
60. Majoros IJ, Myc A, Thomas T, Mehta CB, Baker JR Jr: PAMAM dendrimer-based multifunctional conjugate for cancer therapy: synthesis, characterization, functionality. Biomacromolecules 7(2), 572-579 (2006).
61. McCarthy TD, Karetias P, Henderson SA et al.: Dendrimers as drugs: discovery and preclinical and clinical development of dendrimer-based microbicides for HIV and STI prevention. Mol. Pharm. 2(4), 312-318 (2005).
62. Yuan JJ, Armes SP, Takabayashi Y et al.: Synthesis of biocompatible poly[2-(methacryloyloxy)ethylphosphorylcholine]- coated magnetite nanoparticles. Langmuir 22(26), 10989-10993 (2006).
63. Artemov D, Mori N, Okollie B, Bhujwalla ZM: MR molecular imaging of the Her-2/neu receptor in breast cancer cells using targeted iron oxide nanoparticles. Magn. Reson. Med. 49(3), 403-408 (2003).
64. Zhao M, Beauregard DA, Loizou L, Davletov B, Brindle KM: Non-invasive detection of apoptosis using magnetic resonance imaging and a targeted contrast agent. Nat. Med. 7(11), 1241-1244 (2001).
65. Grimm J, Perez JM, Josephson L, Weissleder R: Novel nanosensors for rapid analysis of telomerase activity. Cancer Res. 64(2), 639-643 (2004).
66. Simberg D, Duza T, Park JH et al.: Biomimetic amplification of nanoparticle homing to tumors. Proc. Natl Acad. Sci. USA 104(3), 932-936 (2007).
67. Bonnemain B: Superparamagnetic agents in magnetic resonance imaging: physicochemical characteristics and clinical applications. A review. J Drug Target 6(3), 167-174 (1998).
68. Jordan A, Wust P, Fahling H et al.: Inductive heating of ferrimagnetic particles and magnetic fluids: physical evaluation of their potential for hyperthermia. Int. J. Hyperthermia 9(1), 51-68 (1993).
69. Moroz P, Jones SK, Gray BN: Magnetically mediated hyperthermia: current status and future directions. Int. J. Hyperthermia 18(4), 267-284 (2002)..
70. Gupta AK, Gupta M: Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials 26(18), 3995-4021 (2005).
71. Johannsen M, Gneveckow U, Taymoorian K et al.: Morbidity and quality of life during thermotherapy using magnetic nanoparticles in locally recurrent prostate cancer: Results of a prospective phase I trial. Int. J. Hyperthermia 23(3), 315-323 (2007).
72. Bertorelle F, Wilhelm C, Roger J et al.: Fluorescence-modified superparamagnetic nanoparticles: intracellular uptake and use in cellular imaging. Langmuir 22(12), 5385-5391 (2006).
73. Jain TK, Morales MA, Sahoo SK, Leslie-Pelecky DL, Labhasetwar V: Iron oxide nanoparticles for sustained delivery of anticancer agents. Mol. Pharm. 2(3), 194-205 (2005).
74. Medarova Z, Pham W, Farrar C, Petkova V, Moore A: In vivo imaging of siRNA delivery and silencing in tumors. Nat. Med. 13(3), 372-377 (2007).
75. Jain RK: Delivery of molecular and cellular medicine to solid tumors. Adv. Drug Deliv. Rev. 46(1-3), 149-168 (2001).
76. Maeda H: The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv. Enzyme Regul. 41 89-207 (2001).
77. Sledge GW Jr, Miller KD: Exploiting the hallmarks of cancer: the future conquest of breast cancer. Eur J. Cancer 39(12), 1668-1675 (2003).
78. Hong S, Lerouell PR, Majoros IJ et al.: The binding avidity of a nanoparticle-based multivalent targeted drug delivery platform. Chem. Biol. 14(1), 107-115 (2007).
79. Montet X, Funovics M, Montet-Abou K, Weissleder R, Josephson L: Multivalent effects of RGD peptides obtained by nanoparticle display. J. Med. Chem. 49(20), 6087-6093 (2006).
80. Saul JM, Annapragada AV, Bellamkonda RV: A dual-ligand approach for enhancing targeting selectivity of therapeutic nanocarriers. J. Control Release 114(3), 277-287 (2006).
81. Steinhauser I, Spankuch B, Strebhardt K, Langer K: Trastuzumab-modified nanoparticles: optimisation of preparation and uptake in cancer cells. Biomaterials 27(28), 4975-4983 (2006).
82. Tiefenauer LX, Kuhne G, Andres RY: Antibody-magnetite nanoparticles: in vitro characterization of a potential tumor-specific contrast agent for magnetic resonance imaging. Bioconjug. Chem. 4(5), 347-352 (1993).
83. Hood JD, Bednarski M, Frausto R et al.: Tumor regression by targeted gene delivery to the neovasculature. Science 296(5577), 2404-2407 (2002).
84. Pasqualini R, Ruoslahti E: Organ targeting in vivo using phage display peptide libraries. Nature 380(6572), 364-366 (1996).
85. Joyce JA, Laakkonen P. Bernasconi M et al.: Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis. Cancer Cell 4(5), 393-403 (2003).
86. Pasqualini R, Koivunen E, Ruoslahti E: Alpha v integrins as receptors for tumor targeting by circulating ligands. Nat. Biotechnol. 15(6), 542-546 (1997).
87. Sun C, Sze R, Zhang M: Folic acid-PEG conjugated superparamagnetic nanciparticles for targeted cellular uptake and detection by MRI. J. Biomed. Mater. Res. A 78(3), 550-557 (2006).
88. Kim IS, Kim SH: Development of polymeric nanoparticulate drug delivery systems: evaluation of nanoparticles based on biotinylated poly(ethylene glycol) with sugar moiety. Int J. Pharm. 257(1-2), 195-203 (2003).
89. Brody EN, Gold L: Aptamers as therapeutic and diagnostic agents. J. Biotechnol. 74(1), 5-13 (2000).
90. Ellington AD, Szostak JW: In vitro selection of RNA molecules that bind specific ligands. Nature 346(6287), 818-822 (1990).
91. Vater A, Klussmann S: Toward third-generation aptamers: Spiegelmers and their therapeutic prospects. Curr. Opin. Drug Discov. Devel. 6(2), 253-261 (2003).
92. Farokhzad OC, Cheng J, Teply BA et al.: Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc. Natl Acad Sci. USA 103(16), 6315-6320 (2006).
93. Bagalkot V, Farokhzad OC, Langer R, Jon S: An aptamer-doxorubicin physical conjugate as a novel targeted drug-delivery platform. Angew Chem. Int. Ed. Engl. 45(48), 8149-8152 (2006).